Does MDD (Medical Devices Directive) review offer opportunity for simplify health technology directives?
This article was originally published in Clinica
A single EU healthcare products directive is needed in a "new Europe that deserves a new Directive with new vision". That is the view of Neil R Armstrong, CEO of Meddiquest in the light of the draft Commission proposal revising the Medical Devices Directive (MDD), the deadline for which (June 25) is about to expire.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.